Abstract-Sepiapterin reductase deficiency (SRD) is a rare, treatable disorder of monoamine metabolism with cognitive delay and L-dopa responsive movement disorder. We describe a patient with SRD and distinctive phenotypic feature of marked hypersomnolence. Our patient showed improvement with therapies directed at both serotonergic and dopaminergic deficiencies. This case illustrates symptoms that characterize the SRD phenotype and demonstrates the importance of systematic treatment trials addressing the various biochemical abnormalities present. NEUROLOGY 2006;67:2032-2035 Jennifer Friedman, MD; Keith Hyland, PhD; Nenad Blau, PhD; and Mia MacCollin, MD Defects in monoamine biosynthesis are associated with various phenotypes including developmental delay, diurnal variation in symptom severity, and dystonia that may improve with levodopa.
apraxia, dysarthric speech, diffuse weakness, bradykinesia, generalized dystonia, myoclonus, and choreoathetosis. Cognitive and motor impairment was incapacitating in the afternoon and improved markedly after a nap. Cranial MRI, 18 Fdeoxyglucose, and 18 F-fluorodopa PET were normal. Sleep study revealed abnormal sleep architecture with low sleep efficiency, shift toward lighter stages, and recurrent awakenings. Periodic limb movements were absent. Multiple sleep-latency testing was unremarkable.
CSF contained markedly reduced 5HIAA and HVA and elevated 7,8-dihydropterin consistent with SRD. Assays of neopterin and biopterin in cytokine-stimulated fibroblasts and sepiapterin reductase (SR) activity in non-stimulated fibroblasts revealed elevated neopterin and markedly reduced biopterin levels as well as SR activity below the level of detection. 4 Mutational analysis of SPR gene revealed a homozygous change (c.448AϾG) predicted to cause missense alteration (p.R150G) (table 1). 4 Sequential treatment trials of L-dopa/carbidopa (6.25 to 100 mg/day L-dopa ), sertraline (50 to 150 mg/day), and selegiline (5 to 10 mg/day) markedly improved alertness, decreased sleep time, and decreased dystonia. L-Dopa/carbidopa was limited by intolerable dyskinesias. Sertraline produced only modest benefit and akathisia. Combination therapy with selegiline and sertraline led to more significant benefit than sertraline alone, but was limited by myoclonic jerks and oral-buccal dyskinesia. Carbidopa/5-hydroxytryptophan (5-HTP; 1.7 mg/kg/day 5-HTP) also markedly improved sleep and dystonia related symptoms but was discontinued due to transaminase elevation. Video documentation of the patient's baseline and response to these medications is available on the Neurology Web site at www.neurology.org. Interestingly, bromocriptine (0.05 to 0.10 mg/day) induced menses that were associated with worsened symptomatology. Melatonin (2 mg/day) decreased nighttime cervical dystonia and eased sleep transition. Tetrahydrobiopterin (BH 4 ; 20 mg/kg/day) produced no benefit, but was given for only 1 week due to cost. Trihexyphenidyl, Lioresal, and benztropine were not tolerated. Maximal benefit was obtained on combination of selegiline and melatonin.
Discussion. This patient shares with other SRD cases core features of dopa-responsive, diurnally fluctuating movement disorder and motor and cognitive delay (table 2) 1-3,5 yet displays several unique features. Oculogyric crises, in contrast to most previous cases, were absent. 2, 3, 5 Remarkably, hypersomnolence, this patient's primary symptom, has not been previously reported. Hypersomnolence and disordered sleep have been noted in other disorders of monoamine biosynthesis. 1 This symptom may be related to impaired dopaminergic or serotonergic influences on sleep and wakefulness. This patient also displays minor features noted in patients with non-SRD disorders of monoamine metabolism.
1 Ptosis, likely due to sympathetic defect, was present. In addition, there were Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the December 12 issue to find the title link for this article. Supported in part by the Swiss National Science Foundation grant no. 310000-107500/1 (to N.B.). irregular menses/amenorrhea, which likely resulted from increased prolactin levels due to loss of pituitary dopamine release. As the core features of SR deficiency are nonspecific and diurnal fluctuation may not always be present, it is crucial to be cognizant of subtle signs, as in our patient, that may suggest monoamine dysfunction. When these are present, further investigation including L-dopa trial, and CSF neurotransmitter and pterins analysis should be undertaken.
Though patients with SRD show dramatic response to L-dopa/carbidopa supplementation, improvement is incomplete. [2] [3] [4] 6, 7 Despite the imperfect clinical response there has previously been no systematic attempt to explore strategies to address the variety of other neurotransmitter and pterin abnormalities present in these patients (table 2) . In this case, we report a variety of treatments: 1) cofactor replacement (BH 4 ); 2) neurotransmitter precursor supplementation (L-dopa and 5-HTP); 3) strategies to block reuptake or reduce catabolism of neurotransmitters (sertraline, selegiline); 4) agonist (bromocriptine); and 5) symptomatic therapy (trihexyphenidyl, Lioresal, benztropine melatonin). For this patient hypersomnolence was the most disabling feature. Melatonin is a downstream byproduct of serotonin production and we hypothesized that disordered sleep patterns were related to reduced melatonin levels. Therapy with melatonin reduced dystonic neck spasms at bedtime and thus eased transition to sleep. No change in overall sleep time or alertness was noted. Interestingly, both serotonergic and dopaminergic agents (5-HTP, sertraline, L-dopa, and selegiline) led to increased arousal and decreased total sleep time. This is consistent with a growing appreciation for the role of both of these neurotransmitters in modulating arousal and sleep/wake states. BH 4 deficiency may lead to impaired nitric oxide (NO) production, as demonstrated in CSF from SR and BH4 deficiency patients. 8 Though the role of NO in the CNS is not fully understood, reduced levels may impact a variety of functions including learning, memory, and sleep through NO's role in modulating the release of neurotransmitters or itself acting as an atypical neurotransmitter. Empiric treatment with BH 4 replacement is unfortunately problematic as very small amounts are able to cross the bloodbrain barrier.
Several of this patient's responses to pharmacologic intervention are not consistent with current understanding of dopaminergic/serotonergic roles in the CNS. Though abnormal involuntary movements and dystonic postures improved with L-dopa/carbidopa, sertraline, and selegiline, most marked improvement was noted with 5-HTP. This is of interest because, though a few reports have demonstrated impaired CNS serotonin metabolism in patients with dystonia, 9 the serotonergic system is not traditionally thought of as playing a prominent role in the generation of dystonia. In addition, levodopa/carbidopa therapy was associated with intolerable hyperkinesias, even at very low doses. Dyskinesias have been reported rarely in patients with genetically confirmed DRD 10 as well as SRD. 2 These observations suggest that nigrostriatal denervation may not be necessary for development of dyskinesia. We hypothesized that dyskinesia likely resulted from receptor supersensitivity due to chronic dopamine deficiency. We speculated that reduction of L-dopa dose and administration over prolonged time periods would lessen dyskinesias. Though dose reduction has resulted in improvement of dyskinesias in other SRD patients 2 in our patient, this was, unfortunately, not the case. The etiology of dyskinesia in this and other patients with SRD remains unclear.
SRD is the most recently described disorder of monoamine biosynthesis. Thus far 13 other cases, including 7 from a presumed founder, have been tabulated in the BIODEF database 2, 3, 5, 7 (tables 1 and 2). Other than mutations from a single founder, most are homozygous, unique mutations in patients with severe phenotype. 3, 5 The mutation present in this case was previously reported in a heterozygous form where it was shown that when expressed recombinantly in E coli, the mutant protein is inactive. 3 Though in most cases, SRD is a recessive disorder, one report describes haploinsufficiency resulting in a mild DRD phenotype. 7 No other symptomatic heterozygotes have been reported. The presence of posturing in the patient's mother and several other maternal relatives raises the possibility that haplo- NA ϭ not available; BH4 ϭ tetrahydrobiopterin; 5HIAA ϭ 5-hydroxyindolacetic acid; HVA ϭ homovanillic acid; -ϭ not assayed; # ϭ case number designations in BIODEF/BIOMDB databases.
insufficiency of the R150G mutation may also cause symptoms.
Further investigation will be necessary to define genotype/phenotype relationships, to optimize pharmacologic therapy, to understand pathogenesis of dyskinesias, to clarify the role of individual monoamines in the sleep/wake disturbance, and to determine how BH 4 deficiency contributes to the phenotype. SRD and other disorders of monoamine metabolism should be considered in all childhood, motor/cognitive disorders and cases of unexplained hypersomnolence. Therapies should be directed at not only dopamine deficiency, but also other biochemical deficiencies present in this disorder. 2,3,5-7 † Signs/symptoms which have been seen in other disorders of monamine metabolism (autosomal dominant and recessive GTP cyclohydrolase deficiency, 6-pyruvoyl-tetrahydropterin synthase deficiency, dihydropteridine reductase deficiency, pterin-4␣-carbinolamine dehydratase deficiency, tyrosine hydroxylase deficiency, aromatic L-amino acid decarboxylase deficiency, dopamine ␤-hydroxylase deficiency).
SR ϭ sepiapterin reductase.
